Drug Trial Radar · NCT02021318
Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa
Last checked: Nov 19, 2026Latest source record: Nov 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
616
Actual
Start
Mar 12, 2014
Primary completion
Mar 23, 2018
Study completion Nov 6, 2019
Sponsor
- Lead sponsor
- Astellas Pharma Europe B.V.Astellas (ALPMY)
- Sponsor type
- Industry
- Collaborators
- Kyntra Bio
- First posted
- Dec 27, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study was to evaluate the efficacy of roxadustat compared to darbepoetin alfa in the treatment of anemia in nondialysis-dependent chronic kidney disease (NDD CKD) participants.
Conditions
- Anemia in Chronic Kidney Disease in Non-dialysis Patients
Interventions
RoxadustatDrug
Oral tablet.
Darbepoetin alfaDrug
Subcutaneous or intravenous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With a Hb Response to Treatment at Two Consecutive Visits During the First 24 Weeks of Treatment Without Rescue TherapyTime frame: Baseline to week 24
Locations
125 sites in 26 countries. Site status is shown where the registry gives one.
Site AT43009
Vienna, Austria
Site BY37503
Brest, Belarus
Site BY37501
Grodno, Belarus
Site BY37506
Minsk, Belarus
Site BY37507
Minsk, Belarus
Site BY37505
Minsk, Belarus
Site BY37502
Vitebsk, Belarus
Site BG35907
Sofia, Bulgaria
Site BG35927
Sofia, Bulgaria
Site BG35916
Varna, Bulgaria
Site HR38505
Karlovac, Croatia
Site HR38504
Slavonski Brod, Croatia
Site HR38510
Zagreb, Croatia
Site HR38502
Zagreb, Croatia
Site HR38509
Zagreb, Croatia
Site CZ42008
Liberec, Czechia
Site CZ42021
Prague, Czechia
Site CZ42018
Nový Jičín, CZ, Czechia
Site FI35810
Helsinki, Finland
Site FR33004
Avignon, France
Site FR33009
Colmar, France
Site FR33010
Grenoble, France
Site FR33062
Limoges, France
Site FR33012
Lyon, France
Site FR33007
Saint-Priest-en-Jarez, France
Site GE99503
Tbilisi, Georgia
Site GE99504
Tbilisi, Georgia
Site GE99502
Tbilisi, Georgia
Site DE49073
Cloppenburg, Germany
Site DE49054
Düsseldorf, Germany
Site DE49065
Hamburg, Germany
Site DE49075
Heilbronn, Germany
Site DE49057
Hoyerswerda, Germany
Site HU36028
Budapest, Hungary
Site HU36029
Budapest, Hungary
Site HU36027
Kistarcsa, Hungary
Site HU36008
Pécs, Hungary
Site HU36046
Velence, Hungary
Site IE35301
Cork, Ireland
Site IL97202
Be’er Ya‘aqov, Israel
Showing 40 of 125 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.